These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 19171333)

  • 1. Does endometrial integrin expression in endometriosis patients predict enhanced in vitro fertilization cycle outcomes after prolonged GnRH agonist therapy?
    Surrey ES; Lietz AK; Gustofson RL; Minjarez DA; Schoolcraft WB
    Fertil Steril; 2010 Feb; 93(2):646-51. PubMed ID: 19171333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective, randomized study.
    Schachter M; Friedler S; Ron-El R; Zimmerman AL; Strassburger D; Bern O; Raziel A
    Fertil Steril; 2008 Oct; 90(4):1087-93. PubMed ID: 18023439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates.
    Acevedo B; Gomez-Palomares JL; Ricciarelli E; Hernández ER
    Fertil Steril; 2006 Dec; 86(6):1682-7. PubMed ID: 17074344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cryopreserved blastocyst transfer: impact of gonadotropin-releasing hormone agonist versus antagonist in the previous oocyte retrieval cycles.
    Lee JR; Choi YS; Jee BC; Ku SY; Suh CS; Kim KC; Lee WD; Kim SH
    Fertil Steril; 2007 Nov; 88(5):1344-9. PubMed ID: 17548083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
    Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
    Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ovarian high response on implantation and pregnancy outcome during controlled ovarian hyperstimulation (with GnRH agonist and rFSH).
    Chen QJ; Sun XX; Li L; Gao XH; Wu Y; Gemzell-Danielsson K; Cheng LN
    Acta Obstet Gynecol Scand; 2007; 86(7):849-54. PubMed ID: 17611831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of poor responders: can outcomes be improved with a novel gonadotropin-releasing hormone antagonist/letrozole protocol?
    Schoolcraft WB; Surrey ES; Minjarez DA; Stevens JM; Gardner DK
    Fertil Steril; 2008 Jan; 89(1):151-6. PubMed ID: 17482177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged gonadotropin-releasing hormone agonist therapy reduced expression of nitric oxide synthase in the endometrium of women with endometriosis and infertility.
    Wang J; Zhou F; Dong M; Wu R; Qian Y
    Fertil Steril; 2006 Apr; 85(4):1037-44. PubMed ID: 16580392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GnRH agonist administration prior to embryo transfer in freeze-all cycles of patients with endometriosis or aberrant endometrial integrin expression.
    Surrey ES; Katz-Jaffe M; Kondapalli LV; Gustofson RL; Schoolcraft WB
    Reprod Biomed Online; 2017 Aug; 35(2):145-151. PubMed ID: 28601378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GnRH agonist and antagonist protocols for stage I-II endometriosis and endometrioma in in vitro fertilization/intracytoplasmic sperm injection cycles.
    Pabuccu R; Onalan G; Kaya C
    Fertil Steril; 2007 Oct; 88(4):832-9. PubMed ID: 17428479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gonadotropin-releasing hormone agonist/antagonist conversion with estrogen priming in low responders with prior in vitro fertilization failure.
    Fisch JD; Keskintepe L; Sher G
    Fertil Steril; 2008 Feb; 89(2):342-7. PubMed ID: 17562336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis.
    Surrey ES; Silverberg KM; Surrey MW; Schoolcraft WB
    Fertil Steril; 2002 Oct; 78(4):699-704. PubMed ID: 12372443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes.
    Weitzman VN; Engmann L; DiLuigi A; Maier D; Nulsen J; Benadiva C
    Fertil Steril; 2009 Jul; 92(1):226-30. PubMed ID: 18675961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Women with advanced-stage endometriosis and previous surgery respond less well to gonadotropin stimulation, but have similar IVF implantation and delivery rates compared with women with tubal factor infertility.
    Matalliotakis IM; Cakmak H; Mahutte N; Fragouli Y; Arici A; Sakkas D
    Fertil Steril; 2007 Dec; 88(6):1568-72. PubMed ID: 17349642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
    Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
    Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Papanikolaou EG; Pozzobon C; Kolibianakis EM; Camus M; Tournaye H; Fatemi HM; Van Steirteghem A; Devroey P
    Fertil Steril; 2006 Jan; 85(1):112-20. PubMed ID: 16412740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of ovarian endometrioma on oocytes and pregnancy outcome in in vitro fertilization.
    Suzuki T; Izumi S; Matsubayashi H; Awaji H; Yoshikata K; Makino T
    Fertil Steril; 2005 Apr; 83(4):908-13. PubMed ID: 15820799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting.
    Ho Yuen B; Nguyen TA; Cheung AP; Leung PC
    Fertil Steril; 2009 Aug; 92(2):499-507. PubMed ID: 18706551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.